For instance, nivolumab (anti-PD-1) usually causes endocrine toxicities; atezolizumab (anti-PD-L1) mainly causes hypothyroidism, nausea, and vomiting; pembrolizumab (anti-PD-1) mainly causes arthralgia, pneumonitis, and hepatic toxicities; and iplimumab (anti-CTLA4) mainly causes skin, gastrointestinal, and renal toxicities. Here, CTLA4 is linked to pneumonitis.